Kocak Z, Garipagaoglu M, Adli M, Uzal M C, Kurtman C
Dept of Radiation Oncology, Trakya University Hospital, Turkey.
J Exp Clin Cancer Res. 2004 Jun;23(2):201-6.
This retrospective analysis was performed to examine the outcome of patients with spinal cord ependymomas treated with surgery and postoperative radiation therapy between 1982 and 1998. There were 10 male and 5 female patients, ranging from 16 to 74 years of age with a median age of 38 years. Surgery was gross total resection in 2 patients, subtotal resection in 10, biopsy in 3. All patients received radiation therapy with a total dose of 40-56 Gy. The 5 and 10 year overall survival rates were 83.3 and 83.3%, respectively. Twelve patients are still alive at a median follow-up period of 70 months. Of the 15 patients, 6 developed recurrent disease on follow-up. The median time to recurrence was 45 months (range: 24-80 months). Local failure within the initial irradiated volume occurred in 3 out of 6 patients who received less than 45 Gy and 2 out of 8 patients treated with more than 45 Gy. Four out of the six failures were salvaged with additional treatment. Re-irradiation was used as a part of salvage or sole treatment in 3 cases. The patient who was salvaged with radiation therapy only died of disease progression 41 months following recurrence and the other two who received a combination of surgery, radiotherapy or chemotherapy were still alive 57 and 30 months following relapse. The present study shows that surgery and post-operative radiation treatment for spinal ependymoma patients resulted in high survival rates. Patients with residual disease after surgery should be treated with radiation therapy with a dose of more than 45 Gy. Re-irradiation may be the treatment of choice for recurrent patients having less than complete resection or no surgery.
本回顾性分析旨在研究1982年至1998年间接受手术及术后放疗的脊髓室管膜瘤患者的治疗结果。患者共15例,其中男性10例,女性5例,年龄16至74岁,中位年龄38岁。2例行全切除,10例行次全切除,3例行活检。所有患者均接受放疗,总剂量为40 - 56 Gy。5年和10年总生存率分别为83.3%和83.3%。中位随访70个月时,12例患者仍存活。15例患者中,6例在随访中出现疾病复发。复发的中位时间为45个月(范围:24 - 80个月)。接受小于45 Gy放疗的6例患者中有3例在初始照射野内出现局部失败,接受大于45 Gy放疗的8例患者中有2例出现局部失败。6例失败患者中有4例经额外治疗后病情得到挽救。3例患者采用再程放疗作为挽救治疗的一部分或唯一治疗方法。仅接受放疗挽救的患者在复发后41个月死于疾病进展,另外2例接受手术、放疗或化疗联合治疗的患者在复发后57个月和30个月仍存活。本研究表明,脊髓室管膜瘤患者接受手术及术后放疗可获得较高生存率。术后有残留病灶的患者应接受剂量大于45 Gy的放疗。对于未完全切除或未接受手术的复发患者,再程放疗可能是首选治疗方法。